Seeing further.


We’re advancing our RNA-based treatments so patients with cancers and rare diseases can enjoy the moments that matter.

Learn More

Transforming Immunity. Restoring Hope.

We’re committed to redefining the treatment of certain cancers and rare diseases.

Learn More

Scientists. Believers. People.

At Idera, we’re working hard to translate our nucleic acid science into life-changing medicines.

Discover Idera

The Latest

Keep up with what’s happening at Idera Pharmaceuticals.


Idera Pharmaceuticals Announces Organizational Update

Antisense Pioneer and Idera Founder Dr. Sudhir Agrawal Set to Retire CAMBRIDGE, Mass. and EXTON,… Read more 

Idera Pharmaceuticals Advances Investigational Treatment – Intratumoral IMO-2125 in Combination with Ipilimumab - for Unmet Need in Anti-PD-1 Refractory Metastatic Melanoma

All objectives successfully met in Phase 1 portion of combination trial and the company is now… Read more 

Idera Pharmaceuticals Presents Clinical Translational and Pre-Clinical Data from IMO-2125 Development Program at the American Association for Cancer Research (AACR) 2017 Annual Meeting

- Clinical Translational Data of Immune Parameters Generated Demonstrate IMO-2125 Mechanism of… Read more 

Learn More


Sun, 30 Apr 2017 11:36:21 GMT

Idera Pharmaceuticals, Inc. Calendar Events

A Collection of Idera Pharmaceuticals, Inc. Calendar Events… Read more 

Learn More